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I am grateful to the Editors for the opportunity to comment
on the essay by Hasty and Vijg. I find many of its assertions
unconvincing, including the authors’ confidence in the ‘almost
universal consensus’ (!) that aging is due to DNA damage
secondary to free radical effects, and that mutations that
extend lifespan in mice do so principally by ‘improved DNA
metabolism’. I am a good deal less certain than Hasty and Vijg
that ‘the single most important molecular endpoint responsible
for a major category of aging-related phenotypes is mutation
accumulation in the somatic cells of an organism during the
course of the aging process’; outside the realm of neoplasia,
the evidence that somatic mutations have any effect on
age-related illnesses is quite weak. The assertion that ‘genetic





 can list dozens of mutations that modulate risks of
cataracts, cancer, diabetes, atherosclerosis and other aspects
of age-related dysfunction. The idea that: ‘Damage to the DNA
of the genome would probably be more critical than damage to
proteins or lipids because the ensuing loss of genetic informa-
tion is essentially irreversible’ is also questionable: there is already
good evidence for alterations in lipid oxidation as a key step
in atherosclerosis, and alteration of protein structure in
cataracts and cerebral amyloidoses, but there is very little evidence
linking somatic cell mutations to any aspect of aging except
neoplasia. Mutations are indeed irreversible, but so is the daily
sloughing of skin and gut cells, phagocytosis of erythrocytes and
apoptosis of immune cells. The key issue is not reversibility, but
rather to decide what fraction of mutations are trivial (such as
mutated albumin genes in a T cell), what fraction are rendered
harmless by cell death and replacement, and what fraction
actually contribute to the synchronized abnormalities in multiple
tissues that lead to the signs and symptoms of aging.
The hypotheses championed by Hasty and Vijg are testable.
Data showing that mice engineered to have excellent antioxi-
dant defences have lower somatic mutation rates as well as
decelerated immune, muscle and skin aging, and extended
longevity would be pretty convincing. Conversely, evidence
that a mouse engineered to have poor antioxidant defences
did indeed have increased DNA damage but retained normal
lifespan and normal rates of immune, muscle and skin aging
would create additional problems for those reluctant to leave
this particular bandwagon.
The controversial question of whether somatic mutations
contribute to the pathology of aging would merit its own ‘Head-




. The topic at
hand, however, is a different one: to what extent can engineered
or spontaneous mutations allegedly leading to accelerated
aging contribute to our understanding of the plain old-fashioned
aging that is gradually turning us into our grandparents? I have
tried to justify my own opinion (i.e. ‘not much, and not without
a lot of careful cross-checking’) in the essay printed above. In
his famous papers introducing the idea of ‘segmental’ aging
syndromes (Martin, 1978, 1990), George Martin compiled a
listing of human mutations that produced changes similar to
those that appear in many old people, and inferred from their
relatively high frequency that many thousands of genetic loci
could influence the aging process. This makes good sense to me,
but I have argued elsewhere (Miller, 1999) for the importance
of distinguishing between the many genes that influence the
quality of aging (i.e. why does one individual retain good eyesight
whereas another retains good immunity and a third avoids
cognitive decline?) and the fewer, more interesting genes that
modulate the pace of the overall aging process as a whole.
Although it is clear from interspecies comparisons that genetic
differences lead dogs to age slower than mice and faster than
horses, it is I think still open to debate as to whether common
genetic polymorphisms within a species do or do not modulate
the fundamental pace of synchronized multisystem decline
in middle-aged individuals, in the way that aging is indeed
retarded by calorie-restricted diets in rodents and by some
endocrine system mutations in mice and dogs.
It is not surprising to note that mutations that interfere with
fundamental cellular processes such as DNA repair, oxidation
resistance, apoptosis or cellular organization lead to dysfunction
in more than one cell type and organ system, including cells
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of the mechanisms by which these molecular alterations
produce their pathological effects deserves careful attention and
strong support, and mutations that affect these pathways
will teach us much about how animals are constructed and
maintained, and how they fail. Such research is of such great
importance that it does not need to be hyped. It does not need
to be marketed as research on ‘accelerated aging’.
I should like to propose a challenge for Hasty, Vijg and other
advocates of pepped-up senescence. Let us develop, together,
a consensus listing of changes normally seen in aging mice,
changes documented in multiple strains and stocks in multiple
laboratories. Such a list might include muscle weakness, poor
immune responses, collagen and crystallin cross-linking,
modulation in several hormone levels, and lower activity and
learning, as well as both non-lethal (e.g. arthritis) and lethal
illnesses. Let us then agree to reserve the term ‘accelerated
aging’ for mutant mice that exhibit, at unusually early ages, at
least 75% of the items on the approved checklist.
One should, I think, be wary of insisting, too early, on a
universal consensus about a process that is still as mysterious
as aging. Fifty years ago we knew as much about aging as
physicians did about infection in the early 1800s, when miasma
theory represented the universal consensus of the educated
elite. Fortunately, things have improved: we now know as
much about aging as scientists knew about infection after
John Snow’s observations on the epidemiology of cholera, which
gave the first, premicroscopic hints that germs could make
people sick. We now have some possibly useful hunches
about how aging undermines homeostasis, why it produces
synchronous dysfunction in so many tissues, and why the speed
of the process differs by as much as 30-fold within the mammals
and as much as 10-fold within some orders of mammals. I
myself think it is too early to have a favourite hypothesis, and
I look to comparative biology and analysis of long-lived mutants
to help select specific mechanistic ideas worth special attention.
Others who have already developed a strong, specific, molecular
intuition about how aging works and how aging is timed
should follow their own inclinations, devising experiments to
test the idea that aging can be slowed (or, though I would bet
against it, perhaps even speeded up) by tweaking their favourite
molecular pathways. Such evidence will need to be stronger
than merely showing that crippling an important defence
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